RABOME

RABOME was launched in 2013 to develop and commercialize a class of drugs based on targeting mesenchymal stem cells(MSCs) to various sites of clinical relevance. Our lead molecule is RAB-001 (LLP2A-ALE) and it employs a particular receptor expressed on the surface of MSCs to target these cells to bone surfaces. The MSCs, whether endogenous or externally injected, direct new bone growth and increase existing bone mass and strength.These cells are also immune-modulating cells and they help in reducing inflammation at the directed sites. These findings have currently been demonstrated in a number of animal models for osteonecrosis, fracture healing, osteoporosis, and inflammatory arthritis. The potential opportunity for RABOME is to develop these drugs addressing a need for effective stem cell treatments in osteonecrosis, fracture healing, osteoporosis, and inflammatory arthritis (including rheumatoid Arth.)

RABOME has four very promising indications for RAB-001 that will be developed for FDA Clinical Trials and,when successful, be commercially viable stem cell pharmaceutical treatments for bone. The first indication, Osteonecrosis, started Phase I Human Clinical Trials by screening patients in November of 2016.